The experimental inhaled gene therapy 4D-710 showed acceptable safety and signs of improving lung function in adults with cystic…
Articles by Marisa Wexler, MS
After starting treatment with Trikafta, people with cystic fibrosis (CF) tend to have less need for inhaled mucus-clearing…
People with cystic fibrosis (CF) who have certain lung structure abnormalities — ones visible on CT scans — are more…
The U.S. Food and Drug Administration (FDA) has approved a new generic form of inhaled tobramycin, an antibiotic that’s…
Sionna Therapeutics has launched a clinical trial to test its experimental therapy SION-719 in combination with Trikafta (elexacaftor/tezacaftor/ivacaftor),…
ARCT-032, Arcturus Therapeutics’ experimental inhaled therapy for cystic fibrosis (CF), has been well tolerated so far in a…
Despite a recent hold by the U.S. Food and Drug Administration (FDA) on a BX004 clinical trial in the U.S.,…
Enrollment has finished in a clinical trial testing the experimental therapy CMTX-101, which is designed to help clear out bacterial…
The Cystic Fibrosis Foundation is making a new investment of up to $11 million in 4D Molecular Therapeutics…
The experimental anti-inflammatory therapy brensocatib was generally well tolerated in adults with cystic fibrosis (CF), according to data from…